Diatrizoate meglumine - Generic Drug Details

What are the generic drug sources for diatrizoate meglumine and what is the scope of freedom to operate?

Diatrizoate meglumine is the generic ingredient in thirty-two branded drugs marketed by Bayer Hlthcare, Bracco, Ge Healthcare, Intl Medication, Mallinckrodt, Liebel-flarsheim, Anda Repository, and Annora Pharma, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for diatrizoate meglumine. One supplier is listed for this compound.

Summary for diatrizoate meglumine

US Patents:	0
Tradenames:	32
Applicants:	8
NDAs:	22
Drug Master File Entries:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	32
Clinical Trials:	1
Patent Applications:	1,319
What excipients (inactive ingredients) are in diatrizoate meglumine?	diatrizoate meglumine excipients list
DailyMed Link:	diatrizoate meglumine at DailyMed

Recent Clinical Trials for diatrizoate meglumine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lawson Health Research Institute	Phase 4

See all diatrizoate meglumine clinical trials

Pharmacology for diatrizoate meglumine

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

Medical Subject Heading (MeSH) Categories for diatrizoate meglumine

Contrast Media

US Patents and Regulatory Information for diatrizoate meglumine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	RENO-60	diatrizoate meglumine	INJECTABLE;INJECTION	010040-016	Approved Prior to Jan 1, 1982		DISCN	No	No
Bracco	CYSTOGRAFIN DILUTE	diatrizoate meglumine	SOLUTION;URETHRAL	010040-022	Nov 9, 1982		RX	Yes	No
Ge Healthcare	HYPAQUE-M,75%	diatrizoate meglumine; diatrizoate sodium	INJECTABLE;INJECTION	010220-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Liebel-flarsheim	MD-GASTROVIEW	diatrizoate meglumine; diatrizoate sodium	SOLUTION;ORAL, RECTAL	087388-001	Approved Prior to Jan 1, 1982	AA	RX	No	No
Ge Healthcare	HYPAQUE-CYSTO	diatrizoate meglumine	SOLUTION;URETHRAL	016403-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Bayer Hlthcare	GASTROVIST	diatrizoate meglumine; diatrizoate sodium	SOLUTION;ORAL, RECTAL	087728-001	Sep 23, 1982		DISCN	No	No
Annora Pharma	DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM	diatrizoate meglumine; diatrizoate sodium	SOLUTION;ORAL, RECTAL	215049-001	Nov 17, 2023	AA	RX	No	No

Diatrizoate meglumine Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Diatrizoate Meglumine

Introduction

Diatrizoate meglumine, a key component in various medical imaging and therapeutic applications, is experiencing significant growth driven by several market dynamics. This article delves into the current market size, growth projections, key drivers, and the financial trajectory of diatrizoate meglumine.

Market Size and Growth Projections

The global meglumine market, which includes diatrizoate meglumine, was valued at USD 0.01 billion in 2023 and is projected to reach USD 0.02 billion by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 4%[1].

However, other reports suggest a slightly higher CAGR of 5.5% from 2022 to 2030, driven by increasing demand in pharmaceutical and industrial applications[3].

Key Drivers of the Market

Increased Demand in the Pharmaceutical Industry

Meglumine is widely used as an excipient in various pharmaceutical formulations, including antibiotics, antiviral, and antifungal drugs. The rapid growth in the pharmaceutical industry due to an increase in chronic and infectious diseases globally is a significant driver for the meglumine market[3].

Adoption in Veterinary Medicine

The use of meglumine in veterinary medicine, particularly for treating parasitic infections in animals, is another driving factor. The growing adoption of pets and increasing expenditure on animal healthcare are contributing to the market growth[3].

Use in Medical Imaging

Diatrizoate meglumine is used with iodinated contrast media in diagnostic imaging procedures such as gastrointestinal studies, angiography, and urography. The rising prevalence of chronic diseases and the subsequent increase in diagnostic procedures have augmented the demand for contrast media, thus driving the demand for diatrizoate meglumine[3][5].

Ability to Aid Drug Solubility

Meglumine enhances the water solubility of drugs, which improves their efficacy. This property makes it a valuable component in drug formulation, further driving its market[3].

Regional Market Dynamics

North America

North America holds a dominant position in the global meglumine market due to its advanced healthcare infrastructure and the high concentration of key market players such as Merck and others[3].

Asia-Pacific

The Asia-Pacific region is expected to witness significant growth due to rapid industrialization and the expanding healthcare sector. The region's growing pharmaceutical industry and increasing expenditure on research and development activities are key factors contributing to this growth[3].

Europe

Europe is also an active player in the global market, driven by stringent regulations and high funding in healthcare research. The region's strong focus on research and development and the presence of key players contribute to its market share[3].

Financial Trajectory

Revenue Growth

The projected growth from USD 0.01 billion in 2023 to USD 0.02 billion by 2032 indicates a steady financial trajectory for the meglumine market, including diatrizoate meglumine. This growth is fueled by the increasing demand in various sectors such as pharmaceuticals, veterinary medicine, and medical imaging[1].

Investment in Research and Development

Key players like Merck, Tianma, Libang Healthcare Group, and New Hualian Pharm are continuously investing in research and development. This investment is expected to open up new opportunities and drive the market forward, contributing to the financial growth of the sector[3].

Opportunities and Challenges

Emerging Markets

The growing healthcare infrastructure and pharmaceutical industries in emerging economies present a promising opportunity for the meglumine market. These regions offer a potential for significant growth due to their expanding healthcare needs and increasing expenditure on healthcare[3].

Personalized Medicine

The trend towards personalized medicine could provide new growth opportunities as it would require innovative formulations, potentially increasing the use of meglumine[3].

Regulatory Challenges

Despite the growth opportunities, the market faces regulatory challenges, particularly in regions with stringent healthcare regulations. Compliance with these regulations can be a challenge but also ensures the safety and efficacy of the products[3].

Clinical Effectiveness and Safety

Use in Intestinal Obstruction and Constipation

A retrospective audit on the use of diatrizoate meglumine in patients with advanced neoplasms showed that it was well tolerated and effective in resolving intestinal obstruction and constipation. The study indicated that 90% of patients experienced resolution of these conditions post-dose[2].

Toxic Effects

High osmolal radiocontrast agents like diatrizoate can have toxic effects on renal cells, including apoptosis, cellular energy failure, and disruption of calcium homeostasis. These effects are thought to be linked to oxidative stress[5].

Key Players

The global meglumine market is dominated by several key players, including:

• Merck
• Tianma
• Libang Healthcare Group
• New Hualian Pharm

These companies contribute significantly to the market's growth through their focus on research and development, expansion, and strategic collaborations[1][3].

Conclusion

The market for diatrizoate meglumine is poised for significant growth driven by its versatile applications in pharmaceuticals, veterinary medicine, and medical imaging. With a projected CAGR of 4% to 5.5% over the next decade, the market is expected to expand substantially. Key players and emerging markets will play crucial roles in this growth, while regulatory compliance and ongoing research will ensure the safety and efficacy of diatrizoate meglumine.

Key Takeaways

• The global meglumine market, including diatrizoate meglumine, is projected to grow from USD 0.01 billion in 2023 to USD 0.02 billion by 2032.
• The market is driven by increased demand in the pharmaceutical industry, adoption in veterinary medicine, and use in medical imaging.
• North America and the Asia-Pacific region are key markets due to their advanced healthcare infrastructure and rapid industrialization.
• Key players such as Merck and Tianma are driving the market through research and development.
• Emerging markets and the trend towards personalized medicine offer significant growth opportunities.

FAQs

1. What is the projected market size of the global meglumine market by 2032? The global meglumine market is projected to touch USD 0.02 billion by 2032[1].

2. What is the CAGR of the meglumine market from 2022 to 2030? The meglumine market is expected to exhibit a CAGR of 5.5% from 2022 to 2030[3].

3. What are the primary uses of diatrizoate meglumine? Diatrizoate meglumine is used in medical imaging procedures such as gastrointestinal studies, angiography, and urography, as well as in treating intestinal obstruction and constipation in patients with advanced neoplasms[2][5].

4. Which regions are expected to show significant growth in the meglumine market? The Asia-Pacific region and North America are expected to show significant growth due to rapid industrialization and advanced healthcare infrastructure, respectively[3].

5. What are the potential challenges facing the meglumine market? The market faces regulatory challenges and potential toxic effects of high osmolal radiocontrast agents on renal cells, which need to be addressed through ongoing research and compliance with regulations[3][5].

Sources

1. Business Research Insights: Meglumine Market Size, Share - [2024 To 2032] Growth Report.
2. PubMed: A retrospective audit on usage of Diatrizoate Meglumine.
3. OpenPR: Global Meglumine Market to Experience 5.5% CAGR from 2022 to 2030.
4. Market Research Intellect: Global Meglumine Diatrizoate Injection Market Size, Trends and Projections.
5. DrugBank: Diatrizoate: Uses, Interactions, Mechanism of Action.